A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
← catalyst calendarNCT06137742 · readout in 14 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Basic science
Enrollment
97actual
Sites
68
Countries
Australia, Belgium, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-17 | actual | When the study began enrolling |
| Primary completion | 2026-09-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-02 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Arterial Hypertension
Interventions
- Drug: PF-07868489
- Drug: Placebo for PF-07868489
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Baseline up to Day 113.
Number of Participants With Change From Baseline in Laboratory Tests Results
measured Baseline up to Day 113
Number of Participants With Vital Sign Abnormalities
measured Baseline up to Day 113
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
measured Baseline up to Day 113
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Baseline up to Day 253
Number of Participants With Change From Baseline in Laboratory Tests Results
measured Baseline up to Day 253
Number of Participants With Vital Sign Abnormalities
measured Baseline up to Day 253
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
measured Baseline up to Day 253
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week24
measured Baseline, Week 24
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed